Table 1 Capacity and Readiness in Federal Capital Territory, Nigeria, for Implementing System-Level Hypertension Control Program within 60 Primary Healthcare Centers
Site Characteristics | No. Sites Responded | Result |
|---|---|---|
Personnel and Training | ||
 Sites with two or more full-time staff, a n (%) | 54 | 54 (90) |
 Number of full-time healthcare professionals, median (IQR) | 60 | 5 (3–8) |
 Full-time community health extension workers, median (IQR) | 60 | 3 (2–5) |
 Full-time nurses, median (IQR) | 60 | 1 (0–2) |
 Full-time doctors (generalists and specialists), median (IQR) | 60 | 0 (0–0) |
 Received CVD training within the past 2 years, n (%) | 55 | 8 (15) |
Hypertension Service Delivery | ||
 Screen for hypertension status, n (%) | 60 | 58 (97) |
 Diagnose hypertension, n (%) | 60 | 56 (93) |
 Confirm hypertension diagnosis, n (%) | 60 | 50 (83) |
 Dispense initial treatment for hypertension, n (%) | 60 | 34 (57) |
 Dispense follow-up treatment for hypertension, n (%) | 60 | 34 (57) |
 Monitor patients with hypertension, n (%) | 60 | 48 (80) |
 Provide long term care for patients with hypertension, n (%) | 60 | 36 (60) |
Equipment and Supplies for Hypertension | ||
 Guidelines, n (%) | 55 | 7 (13) |
 Treatment algorithms, n (%) | 55 | 3 (5) |
 Information, education, and communication, n (%) | 55 | 1 (2) |
 Functional blood pressure apparatus, n (%) | 60 | 55 (92) |
Information Systems | ||
 Use of electronic patient records, n (%) | 60 | 0 (0) |
 Functional landline phone, n (%) | 60 | 13 (22) |
 Functional cellular phone, n (%) | 60 | 29 (48) |
 Functional computer, n (%) | 60 | 10 (17) |
 Access to email or internet, n (%) | 60 | 5 (8) |
Availability of Blood Pressure Lowering Medications | ||
 Angiotensin Converting Enzyme Inhibitor, n (%) | 59 | 10 (17) |
 Angiotensin Receptor Blocker, n (%) | 59 | 3 (5) |
 Beta Blocker, n (%) | 59 | 5 (8) |
 Calcium Channel Blocker, n (%) | 59 | 19 (32) |
 Central acting agent, n (%) | 59 | 11 (19) |
 Fixed Dose Combinations, n (%) | 59 | 4 (7) |
 Diuretic,b n (%) | 59 | 15 (25) |
 Vasodilator, n (%) | 59 | 4 (7) |
 Number of 30-day treatment regimens in stock, median (IQR) | 59 | 0 (0–20) |
 No 30-day treatment regimens in stock, n (%) | 59 | 35 (59) |